At one point, BMS said the facility would house 400 people. That was before Chairman and CEO Chris Boerner replaced Giovanni ...

Opdivo continues to maintain momentum on consistent ... It expects the remaining $400 million to be realized in 2025. Concurrent with the fourth-quarter results, BMY announced an expansion to ...

Some of those sales are cannibalising sales of Opdivo monotherapy and the combination ... with sales around $400 million ahead of expectations. Caforio said there was also significant progress ...

Opdivo/Yervoy was cleared for BRAF V600-positive ... Over the same period, Cotellic sales have shrunk from around $400 million to a little over $50m last year as immunotherapy displaced targeted ...

Opdivo plus Yervoy showed a median overall survival of 23.7 months vs. 20.6 months with lenvatinib or sorafenib in the CheckMate -9DW trial. The overall response rate for Opdivo plus Yervoy was 36 ...

Bristol Myers (BMY) Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.

This approval is grounded in the results from the Phase 3 CheckMate -9DW study, which indicated a notable improvement in overall survival for patients treated with the Opdivo plus Yervoy ...

Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on ...

US pharma major Bristol Myers Squibb (NYSE: BMY) has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients ...

e.l.f. Beauty Inc. $70.10-3.94-5.32% ...